ACET - NASDAQ
Adicet Bio, Inc.
$8.15
+4.1%Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
At a Glance
Live SnapshotAdicet Bio, Inc. Profit Bridge
Profitability Analysis
Adicet Bio, Inc. Income Statement
ACET • NASDAQ
| Adicet Bio, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Jun 2014 | Jun 2013 | Jun 2012 | Jun 2011 | Jun 2010 | Jun 2009 | Jun 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||
0.0 | 0.0 | 0.0 | 25M | 9.7M | 17.9M | 995K | 8.2M | 558.5M | 547M | 510.2M | 499.7M | 499.7M | 444.4M | 412.4M | 346.6M | 322.6M | 359.6M | |
GROSS PROFIT | ||||||||||||||||||
(6.4M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (125K) | (80K) | (5K) | (411.5M) | (395.5M) | (401.4M) | (401.4M) | (362.4M) | (346.6M) | (292.5M) | (267M) | (292.3M) | |
-6.4M | 0.0 | 0.0 | 25M | 9.7M | 17.9M | 870K | 8.1M | 558.5M | 135.4M | 114.7M | 98.3M | 98.3M | 82M | 65.8M | 54.2M | 55.6M | 67.3M | |
OPERATING INCOME | ||||||||||||||||||
(115.7M) | (127.6M) | (152M) | (97.5M) | (71.2M) | (57.1M) | (32.4M) | (23.1M) | (18.9M) | (1K) | (70.4M) | (63.9M) | (63.9M) | (56.7M) | (49.3M) | (44.7M) | (43.7M) | (45.9M) | |
(23M) | (28.3M) | (26.5M) | (26.3M) | (22.2M) | (22.8M) | (8.7M) | (8.4M) | (2M) | (1K) | (65.2M) | (61M) | (63.9M) | (56.7M) | (49.3M) | (44.7M) | (43.6M) | (45.4M) | |
(99.1M) | (99.3M) | (106M) | (71.2M) | (48.9M) | (34.3M) | (23.7M) | (14.7M) | (16.8M) | (5.9M) | (5.2M) | (2.8M) | (0.0) | (0.0) | (0.0) | (0.0) | (153K) | (506K) | |
-122.1M | -127.6M | -152M | -72.6M | -61.4M | -39.2M | -31.4M | -15M | -18.9M | -1K | 44.3M | 34.4M | 34.4M | 25.4M | 16.6M | 9.4M | 11.9M | 21.4M | |
PRE-TAX INCOME | ||||||||||||||||||
(36K) | (4K) | (0.0) | (80K) | (176K) | (134K) | (0.0) | (0.0) | (7M) | (4M) | (2.1M) | (2.1M) | (2.1M) | (2.6M) | (1.6M) | (230K) | (98K) | (145K) | |
5.7M | 10.7M | 10M | 3.7M | -85K | 651K | 938K | 543K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-6.4M | (0.0) | (19.5M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
5.3M | 10.5M | 9.4M | 2.8M | -691K | -302K | 3.3M | 5.1M | -14.9M | 0.0 | 402K | 134K | 134K | -626K | 412K | 765K | 839K | 812K | |
-116.8M | -117.1M | -142.7M | -69.8M | -62.1M | -39.5M | -28.1M | -9.9M | -33.8M | -1K | 44.7M | 34.6M | 34.6M | 24.7M | 17M | 10.2M | 12.7M | 22.2M | |
NET INCOME | ||||||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | -125K | -2.8M | (19K) | -589K | (0.0) | (0.0) | (15.7M) | (12.2M) | (12.2M) | (7.8M) | (8M) | (3.6M) | (4.1M) | (8.7M) | |
-116.8M | -117.1M | -142.7M | -69.8M | -62M | -36.7M | -28.1M | -9.3M | -33.8M | -1K | 29M | 22.3M | 22.3M | 17M | 9M | 6.6M | 8.6M | 13.5M |
SEC Filings
ACET - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-K/A 10-K/A 2025 FY (Amended) FY | May 20, 2026 | December 31, 2025 | 2025 | |
10-Q 10-Q 2026 Q1 Q1 | May 13, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 13, 2026 | May 13, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | April 29, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 28, 2026 | April 27, 2026 | 2026 | |
S-3 S-3 N/A | March 12, 2026 | March 12, 2026 | ||
10-K 10-K 2025 FY FY | March 12, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 12, 2026 | March 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 07, 2026 | January 07, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 29, 2025 | December 26, 2025 | 2025 |
Related Guides
Continue your ACET research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.